Search
Pittsburgh Compound B
go.drugbank.com/drugs/DB15161InvestigationalPittsburgh Compound B is under investigation in clinical trial NCT01723553 (Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD).
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic … For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSatraplatin
go.drugbank.com/drugs/DB04996InvestigationalFood and Drug Administration (FDA) approval and is not available in retail pharmacies. … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.
Bezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Products: BEZAFIBRAT 400 RET 1A PHAR, Bezafibrat Genericon retard 400 mg FilmtablettenAphidicolin
go.drugbank.com/drugs/DB17742ExperimentalIt inhibits DNA polymerase alpha and blocks DNA replication.[A259157, A259162]
Synonyms: 8,11a-methano-11ah-cyclohepta(a)naphthalene-4,9-dimethanol, tetradecahydro-3,9-dihydroxy-4,11b-dimethyl-, (3r,4r,4ar,6as,8r,9r,11as,11bs)-Enrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedEnrofloxacin is approved by the FDA for its veterinary use. … Due to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry.
EA-230
go.drugbank.com/drugs/DB19114InvestigationalEA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).
Conjugated estrogens
go.drugbank.com/drugs/DB00286ApprovedInvestigational[T484] The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.[L5608] … It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesImidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the traden...